Q Quince Therapeutics, Inc.: directors' dealings · United States · SEC (Form 4) Explore the full management transaction log of Quince Therapeutics, Inc., a listed equity based in United States. Shares are listed on US US, under the supervision of SEC (Form 4). Market capitalisation: €22m. The latest transaction was reported on 3 September 2024 (Acquisition). Among the most active insiders: Lamond David. The full history is accessible without an account.
€568,671
12 ops.
Buy Volume
Buys €568,671 €1,726 Sells
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Last declaration on 3 September 2024
All Executives17 Thresholds0 Prospectus0 Other0
Declarations 17 total
▲ CEO AND CHIEF MEDICAL OFFICER · Executives · 29 Aug 2024
77,500 shares @ US$0.69 16.9% of flow Common Stock SEC:0001415889-24-022702:0
Ideal exit: 26 May 2025 (T+270) ▲ PRESIDENT · Executives · 20 Aug 2024
48,387 shares @ US$0.65 100.0% of flow Common Stock SEC:0001415889-24-022054:0
Ideal exit: 17 May 2025 (T+270) ▲ CHIEF BUSINESS OFFICER AND COO · Executives · 19 Aug 2024
2,155 shares @ US$0.58 1.0% of flow Common Stock SEC:0001415889-24-021869:0
Ideal exit: 16 May 2025 (T+270) ◇ CHIEF BUSINESS OFFICER AND COO · Executives · 4 Jun 2024
56,061 shares @ US$0.55 25.9% of flow Common Stock SEC:0001415889-24-015533:0
◇ CHIEF EXECUTIVE OFFICER · Executives · 16 Jan 2024
90,531 shares @ US$0.55 15.9% of flow Common Stock SEC:0001415889-24-001313:0
▲ Director · Executives · 12 Dec 2023
300 shares @ US$1.00 0.1% of flow Common Stock SEC:0001209191-23-058694:0
Ideal exit: 7 Sept 2024 (T+270) ▲ Director · Executives · 5 Dec 2023
19,123 shares @ US$1.01 8.5% of flow Common Stock SEC:0001209191-23-057799:0
Ideal exit: 31 Aug 2024 (T+270) ▲ Director · Executives · 29 Nov 2023
14,378 shares @ US$0.98 6.1% of flow Common Stock SEC:0001209191-23-057053:0
Ideal exit: 25 Aug 2024 (T+270) ▲ Director · Executives · 30 Aug 2023
41,026 shares @ US$1.31 23.3% of flow Common Stock SEC:0001209191-23-047880:0
Ideal exit: 26 May 2024 (T+270) ▲ Director · Executives · 15 Aug 2023
107,886 shares @ US$1.32 62.0% of flow Common Stock SEC:0001209191-23-046402:0
Ideal exit: 11 May 2024 (T+270) ▲ Chief Executive Officer · Executives · 10 Aug 2023
88,000 shares @ US$1.26 35.4% of flow Common Stock SEC:0001209191-23-045432:0
Ideal exit: 6 May 2024 (T+270) ▲ Chief Executive Officer · Executives · 8 Aug 2023
80,000 shares @ US$1.24 31.7% of flow Common Stock SEC:0001209191-23-045235:0
Ideal exit: 4 May 2024 (T+270) ▲ Chief Business Officer · Executives · 8 Aug 2023
71,762 shares @ US$1.22 73.1% of flow Common Stock SEC:0001209191-23-045234:0
Ideal exit: 4 May 2024 (T+270) ▲ Director · Executives · 8 Aug 2023
8,000 shares @ US$1.23 100.0% of flow Common Stock SEC:0001209191-23-045231:0
Ideal exit: 4 May 2024 (T+270) ▼ Chief Accounting Officer & VP · Executives · 6 Mar 2023
1,871 shares @ US$0.98 32.2% of flow Common Stock SEC:0001209191-23-016507:0
● Chief Accounting Officer & VP · Executives · 5 Dec 2022
1,640 shares @ US$0.72 20.9% of flow Common Stock SEC:0001209191-22-060218:0
● Chief Accounting Officer & VP · Executives · 6 Sept 2022
1,520 shares @ US$1.64 47.0% of flow Common Stock SEC:0001209191-22-049221:0